← Back to Search

Dynamic FAZA PET and Multiparametric MR Imaging for Brain Tumor

Phase < 1
Waitlist Available
Led By Caroline Chung
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cervical Cohort: Adult females (>18 years old) with newly diagnosed cervical cancer who are able to provide informed consent, receiving surgery, radiotherapy, or chemotherapy, and have no contraindications to MRI with gadolinium contrast or 18F-FAZA PET
Glioma Cohort: Adult patients (> 18 years old) with newly diagnosed or recurrent high grade glioma with newly confirmed pathology (within 1 month) who are able to provide informed consent and have no contraindications to MRI with gadolinium contrast or 18F-FAZA PET
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is investigating if brain tumors with greater hypoxia, as defined by qBOLD and 18F-FAZA PET, have certain pathological features including proportionate necrosis, Ki-67 and IDH mutation status.

Who is the study for?
This trial is for adults over 18 with high grade glioma (brain tumor) or newly diagnosed cervical cancer. Participants must be receiving surgery, radiotherapy, or chemotherapy and have no issues with MRI or PET scans using specific contrasts. They should be able to give informed consent.
What is being tested?
The study is testing the use of dynamic FAZA PET scans and multiparametric MR imaging to evaluate oxygen levels, metabolism, and blood supply in brain tumors and cervical cancers. It aims to understand how these factors relate to each other.
What are the potential side effects?
Since this trial involves diagnostic procedures rather than treatments, side effects are minimal but may include discomfort from lying still during imaging and potential reactions to contrast agents used in MRI or PET scans.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am an adult woman with new cervical cancer, getting treatment, and can have MRI or PET scans.
Select...
I am an adult with a new or returning high-grade brain tumor and can undergo MRI and PET scans.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18F-FTXExperimental Treatment1 Intervention
The radioactive tracer (FAZA)

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,070 Previous Clinical Trials
1,802,788 Total Patients Enrolled
Caroline ChungPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
213 Total Patients Enrolled

Media Library

18F-FTX Clinical Trial Eligibility Overview. Trial Name: NCT05047913 — Phase < 1
Cervical Cancer Research Study Groups: 18F-FTX
Cervical Cancer Clinical Trial 2023: 18F-FTX Highlights & Side Effects. Trial Name: NCT05047913 — Phase < 1
18F-FTX 2023 Treatment Timeline for Medical Study. Trial Name: NCT05047913 — Phase < 1
~1 spots leftby Apr 2025